← FDA DRUG APPROVALS

FDA BLA · BLA761451

SAPHNELO

anifrolumab-fnia

Sponsor: ASTRAZENECA AB

APPLICATION
BLA761451
TYPE
BLA
ORIGINAL APPROVAL
2026-04-24
LATEST ACTION
2026-04-24
ROUTE
SUBCUTANEOUS, SINGLE-USE
DOSAGE FORM
INJECTION, VIAL
MARKETING STATUS
Prescription

Products

SAPHNELOPrescription
ANIFROLUMAB-FNIA 120MG/0.8ML · INJECTION
SAPHNELOPrescription
ANIFROLUMAB-FNIA 300MG/2ML (150MG/ML · VIAL · SINGLE-USE

Approval history

2026-04-24Type 5 - New Formulation or New Manufacturer · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →